• Be willing and able to provide written informed consent/assent for the trial.

• Be ≥ 21 years of age on day of signing informed consent.

• Histologically proven invasive breast carcinoma with triple negative receptor status (Estrogen receptor, Progesterone receptor and HER2 negative by IHC and FISH). Patients who are weekly positive for the estrogen or progesterone receptor (i.e., \< or = 10%) are eligible.

• Clinically ≤ 3 cm unifocal lesion by imaging or physical examination.

• Clinically node negative, no evidence of metastatic disease.

• No prior anti-cancer therapy including investigational agents, radiation therapy, or breast resection within 6 months of study entry.

• Breast size B cup or larger, to allow for IORT procedure.

• Have a performance status of 0 or 1 on the ECOG Performance Scale.

• Demonstrate adequate organ function.

⁃ Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

⁃ Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication.